Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03084014 in Japanese patients with advanced solid tumors
NCT02462707Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Jul 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of nirogacestat in solid tumor (advanced stage), sponsored by Pfizer. Primary endpoint: First-cycle Dose Limiting Toxicities at 28 days. Planned start Jul 2015; status: withdrawn.
02
Drugs
nirogacestat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02462707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462707.